Patients with inflammatory bowel disease who started a GLP-1 drug for obesity or diabetes did not have a lower risk of their bowel disease flaring, according to a large analysis of United States insurance claims.
The finding, reported by Medscape from a study published online in Clinical Gastroenterology and Hepatology, tests a hypothesis that had gathered real momentum. Obesity has been linked to worse outcomes in Crohn's disease and ulcerative colitis, and laboratory work suggested GLP-1 signaling might calm gut inflammation directly. Several earlier retrospective studies pointed toward benefit.
